A disciplined, highly targeted approach to discovering new cancer medicines
Rigorous, definitive clinical trials based on deep biology and chemistry expertise
Committed to bringing differentiated new cancer medicines to patients
ARIAD's first internally discovered and developed medicine
ARIAD to Webcast Conference Call on First Quarter 2014 Financial Results
ARIAD Announces Appointment of Hugh Cole, Senior Pharmaceutical-Industry Executive, as Chief Business Officer
A shared commitment to patients and each other. This is ARIAD.
click here for PDF